Superluminal Medicines secured an oversubscribed $60 million Series B to advance its obesity program toward a first-in-human clinical study. The company said the funding supports continued pipeline execution for next-generation small-molecule GPCR-targeted therapies across endocrine and cardiometabolic diseases. Superluminal’s platform combines AI/machine learning with protein dynamics and structural biology to pursue challenging GPCR targets. The company’s pitch emphasizes modality integration to reduce uncertainty in target engagement and program selection. The financing adds momentum to obesity drug development as companies compete on potency, selectivity, and tolerability while aiming to accelerate entry into clinical testing.